Idaho Clinical Trials Report — June 2026

For Idaho residents considering participation in clinical research, June 2026 presents both urgent opportunities and exciting new avenues to contribute to medical science. Across the state, 331 clinical trials are currently recruiting, spanning 21 cities and 181 research sites. However, a critical window is closing for several studies, with 14 trials slated to conclude enrollment within the next 90 days.

Among these closing trials, there is still a chance for healthy volunteers to participate in 1 study. For individuals with specific health conditions, time is also running out to explore options in trials focused on a range of health challenges. Conditions with trials closing soon include:

• Vulvovaginal candidiasis (VVC)
• Atopic dermatitis
• Chickenpox
• Chronic granulomatous disease (CGD)
• COPD
• Idiopathic short stature
• Major depressive disorder
• Metastatic small intestinal adenocarcinoma
• Nonsegmental vitiligo
• Post concussive syndrome

If you or someone you know is affected by these conditions, we encourage you to investigate these opportunities promptly before they close to new participants.

New Research Horizons Emerge Across Idaho

This month, Idaho welcomes 8 new clinical trials, matching the number of new studies that opened in May 2026. These new initiatives bring significant opportunities, particularly in metabolic health, infectious disease prevention, and specific cancer research. Notably, all 8 of these new trials are sponsored by industry leaders, indicating a strong focus on developing new pharmaceutical and device-based interventions.

A significant portion of this month's new research is dedicated to conditions related to weight management and diabetes. Conditions addressed by these new studies include:

• Chronic weight management (2 trials)
• Obesity (2 trials)
• Overweight (2 trials)
• Pneumococcal disease (2 trials)
• Type 2 diabetes mellitus (3 trials, including variations in naming)
• Idiopathic pulmonary fibrosis (IPF) (1 trial)
• Localized prostate cancer (1 trial)

Among the new trials, 5 are drug-based interventions, 2 are biological, and 1 involves a device, offering a diverse range of participation options.

Major Sponsors Drive Cutting-Edge Trials

Several prominent pharmaceutical companies are launching significant Phase 2 and Phase 3 trials in Idaho this month, bringing advanced research opportunities to local communities. These studies represent substantial efforts to address widespread health concerns:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring two pivotal Phase 3 trials for weight management. NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," is a global study aiming for 3,600 participants to evaluate the long-term efficacy and safety of aleniglipron. Their second study, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," will enroll 1,100 participants to assess aleniglipron in those with both overweight/obesity and Type 2 Diabetes Mellitus.
• Pfizer is leading two crucial Phase 3 vaccine trials targeting pneumococcal disease. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," seeks 3,230 participants to understand the safety and immune response of a new vaccine in infants. Concurrently, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to evaluate a new pneumococcal vaccine in older children and adolescents.
• AstraZeneca is sponsoring two important studies. NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," is a Phase 3 trial for 1,200 participants with Type 2 Diabetes Mellitus and increased cardiovascular risk. Additionally, NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF," is a Phase 2 study for 359 participants with Idiopathic Pulmonary Fibrosis (IPF).
• Eli Lilly and Company is initiating NCT07668336, a Phase 3 study titled "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes." This trial will involve 170 pediatric participants aged 10 to less than 18 years, comparing the efficacy and safety of two diabetes medications.
• For men with localized prostate cancer, PROCEPT BioRobotics is sponsoring NCT07650448, "WATER IV PCa (AS Sub-study)." This study aims to enroll 333 participants to evaluate the safety and efficacy of Aquablation therapy.

Opportunities for Healthy Volunteers and Diverse Participants

For those without a specific medical condition, there are valuable opportunities to contribute to medical research. Of the 8 new trials launched this month, 3 are actively seeking healthy volunteers. Statewide, a total of 29 clinical trials are currently recruiting healthy participants, offering various ways to support medical advancements.

Clinical trials in Idaho are designed to be inclusive, welcoming a broad range of participants. Of the new trials, 3 include children, and 5 include older adults, ensuring that research benefits diverse age groups. While no new trials are female-only this month, 1 new trial is specifically seeking male participants.

Geographic Spread: Research Expanding Across Idaho

Idaho's clinical research footprint continues to grow, with new trials opening in several key locations. This month's new studies are distributed across 6 cities, expanding access to cutting-edge research beyond the state's largest metropolitan areas:

• Ammon (3 new trials)
• Boise (3 new trials)
• Idaho Falls (2 new trials)
• Meridian (2 new trials)
• Blackfoot (1 new trial)
• Rexburg (1 new trial)

This distribution highlights a commitment to making clinical trial participation accessible to more residents across the state, from the Treasure Valley to Eastern Idaho.

As June progresses, we anticipate continued growth in research opportunities, particularly in areas like metabolic health and vaccine development, offering Idahoans diverse avenues to engage with and benefit from medical innovation.